Lysyl Oxidase, Semaphorin 7a and Semaphorin 3a in Patients With Systemic Sclerosis
试验速览
- 阶段
- 不适用
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Fibrin Enzyme Levels in Blood
研究概览
简要总结
The aim of our study is to find a biomarker for fibrosis or vasculopathy in systemic sclerosis. We will evaluate a possible correlation between semaphorin 7a, semaphorin 3a and lysyl oxidase and fibrosis (lung and skin) or vasculopathy in patients with systemic sclerosis. The results obtained may help us diagnose these complications of systemic sclerosis and hopefully even monitor patient treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years(Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Systemic Sclerosis Patients
- •Written consent to participation in study
排除标准
- •Serious active medical condition
- •Other autoimmune rheumatic disease
- •Current or past allergic/inflammatory reaction
- •Liver disease
- •Pregnant or breastfeeding
- •Illegal drug or alcohol abuse
研究组 & 干预措施
Systemic sclerosis patients
Systemic sclerosis patients will have blood tested for fibrotic enzyme levels
干预措施: Blood test (Other)
结局指标
主要结局
Fibrin Enzyme Levels in Blood
时间窗: Six months
Patients will undergo blood tests before study and after six months to determine levels of lysyl oxidase, semaphorin 7a and 3a and thus determine severity of the disease (systemic sclerosis).
次要结局
未报告次要终点
